NCTN Breast Cancer Trials Portfolio (Open as of 9/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant

S2212 (SCARLET)
TNBC
T2-4/N0/M0, or T1-3/N1-2/M0

S2206
HR+/HER2-
Stage II or III

Post-Neoadjuvant

A012103 (OptimICE-PCR)
TNBC
Early-Stage, pCR post pre-op chemo + pembrolizumab

A012303 (ShortStop-HER2)
HER2+
Early-Stage, pCR post pre-op chemo + HER2 blockade

Adjuvant

NRG-BR009 (OFSET)
HR+/HER2-
pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients

EA1242 (RxFINE-Low)
HR+/HER2-
pT0-3/N0-3/M0, Oncotype Recurrence Score ≤ 25, Postmenopausal patients

Metastatic

S2511
HER2+
De Novo, Stage IV oligometastatic (≤ 5 lesions)

EAY191 (ComboMATCH)

Legend by Subtype Status

Green = TNBC

Orange = HER2+ (Any HR status)

Purple = HR+ and HER2-

Pink = Cross-disease trial

NCTN Breast Cancer Trials (Open as of 9/15/2026)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012303	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
EA1242	III	A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS</=25 (RxFINE-Low)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
S2511	III	Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer with Response to Initial Chemotherapy
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/